Zacks Research Issues Negative Outlook for Omnicell Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research cut their Q3 2026 earnings per share estimates for Omnicell in a report issued on Thursday, February 26th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.25 per share for the quarter, down from their prior estimate of $0.29. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2026 earnings at $0.28 EPS.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.07). The company had revenue of $313.98 million for the quarter, compared to analyst estimates of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

A number of other research firms also recently issued reports on OMCL. Piper Sandler reiterated an “overweight” rating and set a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Wall Street Zen downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings upgraded Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, February 9th. Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a report on Wednesday, February 4th. Finally, Benchmark lifted their price target on Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.50.

Omnicell Stock Down 2.0%

OMCL stock opened at $41.10 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. The company’s 50-day moving average price is $45.05 and its 200 day moving average price is $37.92. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.00. The company has a market cap of $1.84 billion, a P/E ratio of 1,027.76, a P/E/G ratio of 1.47 and a beta of 0.78.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the transaction, the executive vice president owned 91,674 shares of the company’s stock, valued at $4,574,532.60. This represents a 6.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 2.52% of the company’s stock.

Hedge Funds Weigh In On Omnicell

Several large investors have recently added to or reduced their stakes in the business. Cerity Partners LLC boosted its stake in Omnicell by 4.9% in the 4th quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after buying an additional 354 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Omnicell by 6.6% during the 3rd quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock worth $196,000 after acquiring an additional 401 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock worth $1,013,000 after acquiring an additional 424 shares during the last quarter. Martin & Co. Inc. TN grew its holdings in Omnicell by 0.4% in the third quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock valued at $3,706,000 after purchasing an additional 443 shares during the period. Finally, Legal & General Group Plc grew its holdings in Omnicell by 0.3% in the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after purchasing an additional 448 shares during the period. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.